Skip to content
OpenCapital
Get started

Protagonist Therapeutics PTGX Q3 2025 earnings

Reported November 6, 2025 · Before market open

Revenue$4.7MMiss by $10.2M
EPS-$0.62Miss by $0.03
Revenue estimate$14.9M
EPS estimate-$0.59

Next report

Aug 5, 2026 (In 1 week)
Revenue estimate$199.8M
EPS estimate$2.11

Financials

Q3 2025

Income statement

See full
Revenue$4.7M+0.8%
Operating income-$46.4M-12.0%
Net income-$39.3M-18.5%
EPS (diluted)-$0.62-14.8%

Balance sheet

See full
Cash & equivalents$113.7M-13.3%
Total debt$10.7M-1.4%
Total equity$645.4M+21.3%
Total assets$701.7M+16.2%

Cash flow

See full
CapEx$88.0K-88.6%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$4.13B+49.8%
Enterprise value$4.03B+52.7%
P/E90×—
P/S19.8×+11.2×

Profitability

See full
Operating margin9.1%—
Net margin21.9%—

Returns & leverage

See full
Return on equity7.8%—
Debt / equity0×0.0×
Current ratio13×+2.4×

Segments

By segment

See full
Single Reportable$4.7M+0.8%

Versus estimates

Revenue

Q1 2026$56.4MBeat by $44.7MQ4 2025$7.4MMiss by $1.3M
Q3 2025$4.7MMiss by $10.2M
Q2 2025$5.5MMiss by $2.9MQ1 2025$28.3MBeat by $21.8MQ4 2024$170.6MBeat by $89.6M

Diluted EPS

Q1 2026$0.05Beat by $0.70Q4 2025-$0.69Miss by $0.16
Q3 2025-$0.62Miss by $0.03
Q2 2025-$0.55Miss by $0.02Q1 2025-$0.19Beat by $0.31Q4 2024$1.98Beat by $1.92

Ask the moment Protagonist Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Protagonist Therapeutics report Q3 2025 earnings?
Protagonist Therapeutics (PTGX) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Protagonist Therapeutics's Q3 2025 revenue and EPS?
Protagonist Therapeutics reported revenue of $4.7M and eps of $-0.62 for Q3 2025.
Did Protagonist Therapeutics beat estimates in Q3 2025?
Revenue missed the consensus estimate of $14.9M by $10.2M. EPS missed the consensus estimate of $-0.59 by $0.03.
How did Protagonist Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 0.8% from $4.7M a year earlier and eps declined 14.8% from $-0.54.
Where can I find Protagonist Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-107753) and the 10-Q periodic report (0001104659-25-107816) directly on SEC EDGAR. The filing index links above go to sec.gov.